Development and validation of a high throughput LC–MS/MS method for simultaneous quantitation of pioglitazone and telmisartan in rat plasma and its application to a pharmacokinetic study
Management of cardiovascular risk factors in diabetes demands special attention due to their co-existence. Pioglitazone (PIO) and telmisartan (TLM) combination can be beneficial in effective control of cardiovascular complication in diabetes. In this research, we developed and validated a high thr...
Similar Items
-
Development and validation of a LC- MS/MS Method for simultaneous quantitation of telmisartan and pioglitazone in rat plasma
by: Das, Arindam, et al.
Published: (2016) -
Assessment of preclinical pharmacokinetics and acute toxicity of pioglitazone and telmisartan combination
by: Sengupta, Pinaki Ranjan, et al.
Published: (2017) -
LC-MS-MS development and validation for simultaneous quantitation of metformin, glimepiride and pioglitazone in human plasma and its application to a bioequivalence study
by: Sengupta, Pinaki, et al.
Published: (2009) -
LC-MS/MS simulatneous determination of itopride hydrochloride and domperidone in human plasma
by: Bose, Anirbandeep, et al.
Published: (2009) -
Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat
by: Sengupta, Pinaki, et al.
Published: (2016)